A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma

Mohamad Bassam Sonbol, Talal Hilal, Amylou C. Dueck, Allison C. Rosenthal, Christopher R. Conley, Heidi E. Kosiorek, Brenda F. Ginos, Katherine M. Gano, Craig S. Nichols, Jose F. Leis, Patrick B. Johnston, Thomas M. Habermann, Donald W. Northfelt, Peter Leif Bergsagel, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Craig B. Reeder

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences